Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

BONE SCAN WITH 99MTC-MIBI USED TO DISTINGUISH MALIGNANCIES FROM BENIGN BONE ENTITIES

7th Congress of the European Federation of National Associations of Orthopaedics and Traumatology, Lisbon - 4-7 June, 2005



Abstract

Aim: In the present study we examine the role of bone scan with 99mTc-MIBI, following a positive 99mTc-MDP scan, in the work up to differentiate between malignant and benign bone lesions.

Material and methods: Fifty-nine patients, with a positive 99mTc-MDP bone scan had further investigation of the affected area with the oncophilic radiopharmaceutical 99mTc-MIBI (15 mCi). The agent was administered IV and images were obtained (planar/SPECT) 20 min and 3 hours later. All patients had biopsy and CT/MRI imaging.

The 99m Tc-MIBI images were estimated by 3 independent observers and every abnormal uptake, ranging from faint to intense, was considered positive.

Results: 32 patients had benign bone lesions according to histology pathology; 28 of them (87.5%) had a negative 99mTc-MIBI scan (trauma, benign bone tumors). Four patients with benign bone lesions had positive 99mTc-MIBI (chronic osteomyelitis,osteochondroma, osteochondroblastoma, chondroblastoma). 27 patients had malignant bone tumors proven by biopsy; 25 of them (92.6%) had possitive 99mTc-MIBI scans (sarcomas and metastases) and 2 negative (chondrosarcoma, MFH).

Conclusions: The 99mTc-MIBI scan in patients with positive 99mTc-MDP scan and a high index of suspicion for malignancy (either primary or metastatic) was found to have a high negative pedictive value (NPV=0.875) in excluding the presence of malignancy and a high positive pedictive value (PPV=0.926) in identifying patients with malignancy. The 99mTc-MIBI was positive in all patients with metastatic disease (PPV=1.00). We suggest the use of 99mTc-MIBI as a useful method in decision-making in cases with bone pathology.

Theses abstracts were prepared by Professor Roger Lemaire. Correspondence should be addressed to EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.